In a significant development for surgical visualization technology, medical device manufacturer KARL STORZ has secured US Food and Drug Administration (FDA) clearance for its RUBINA Lens exoscope. This regulatory milestone marks a pivotal expansion of the company’s portfolio, transitioning its advanced near-infrared (NIR) imaging capabilities from the domain of minimally invasive surgery (MIS) into the complex, high-stakes environment of open surgery.
By merging high-definition 4K digital imaging with real-time fluorescence visualization, the RUBINA Lens is poised to redefine how surgeons navigate complex anatomy. This technology allows clinicians to toggle seamlessly between standard white-light visualization and NIR imaging, utilizing indocyanine green (ICG) to reveal physiological details—such as tissue perfusion and lymphatic pathways—that remain invisible to the naked eye.
The Core Innovation: Bridging the Gap in Open Surgery
The RUBINA Lens is not merely a camera; it is an integrated diagnostic and navigational tool designed to eliminate the "blind spots" often associated with traditional open surgical techniques. In an open procedure, a surgeon’s ability to assess the health of tissues relies heavily on visual cues and tactile feedback. The RUBINA Lens augments this by providing a digital, 4K-magnified view on a monitor, which can be shared across the entire surgical team.
Technical Specifications and Capabilities
The device is engineered for versatility and ergonomic efficiency. Key features that distinguish the RUBINA Lens include:
- Integrated NIR/ICG Fluorescence: The system allows for the instantaneous overlay of fluorescence data, critical for assessing blood flow (perfusion) in reconstructed tissues or identifying sentinel lymph nodes.
- Workflow Integration: Crucially, the lens is compatible with the existing KARL STORZ IMAGE1 S RUBINA imaging platforms. This means hospitals can upgrade their surgical capabilities without the prohibitive costs of acquiring entirely new capital equipment.
- Ergonomic Flexibility: The exoscope can be operated as a handheld unit for precise, close-up maneuvering or attached to a mechanical holding arm for steady, hands-free visualization throughout prolonged procedures.
- Operational Efficiency: The device features a wide working distance, significantly reducing the frequency with which surgeons must stop to refocus the camera. Furthermore, its large 16:9 field of view and manual horizon control ensure that orientation remains constant, regardless of the angle of approach.
A Chronology of Innovation: From Endoscopy to Open Surgery
The journey toward the FDA clearance of the RUBINA Lens is part of a broader trajectory of innovation at KARL STORZ. The company has long been a leader in endoscopic systems, where NIR/ICG fluorescence has become a gold standard for colorectal, urological, and gynecological surgeries.
- Early Development: KARL STORZ initially pioneered the IMAGE1 S RUBINA platform for laparoscopic and robotic-assisted surgeries, focusing on the high-contrast visualization of ICG to help surgeons identify tumor margins and vascular structures.
- Global Expansion: Recognizing the potential for this technology in open procedures—where laparoscopy may not be applicable due to patient anatomy or surgical requirements—the company developed the RUBINA Lens exoscope.
- International Adoption: Prior to its US market entry, the RUBINA Lens underwent rigorous evaluation and regulatory approval in various international markets, where it was successfully integrated into oncology and reconstructive surgery workflows.
- FDA Clearance (2026): After fulfilling the stringent requirements for safety and efficacy stipulated by the FDA, the device received the green light for use in the United States, effectively democratizing the use of advanced fluorescence imaging across all surgical disciplines.
Supporting Data: Why ICG Fluorescence Matters
The clinical utility of indocyanine green (ICG) has been extensively documented in medical literature over the past decade. When injected intravenously, ICG binds to plasma proteins and becomes fluorescent when exposed to specific near-infrared light wavelengths.
Clinical Applications
- Tissue Perfusion Assessment: In reconstructive breast surgery, ensuring the viability of flaps—tissue moved from one part of the body to another—is essential. The RUBINA Lens allows surgeons to observe the "wash-in" of blood flow in real-time, preventing complications such as tissue necrosis.
- Lymphatic Mapping: Identifying sentinel lymph nodes is a cornerstone of cancer staging. Fluorescence imaging allows for the precise tracking of lymphatic drainage, leading to more accurate biopsies and potentially less invasive surgical interventions.
- Vascular Integrity: During complex abdominal or thoracic surgeries, visualizing the patency of vessels can be the difference between a successful anastomosis and a life-threatening leak.
Studies have consistently shown that the use of intraoperative fluorescence imaging can lead to changes in surgical strategy in approximately 10-15% of cases, as surgeons identify structures or perfusion deficits that were not apparent under traditional white-light visualization.
Official Perspectives: The Value of Seamless Integration
The industry response to the clearance of the RUBINA Lens has been positive, particularly among hospital administrators and surgeons who prioritize workflow efficiency.
Fernando Morales, Vice President of Surgical and OR Integration at KARL STORZ US, emphasized the importance of the device’s design philosophy. "The Rubina Lens extends real-time fluorescence visualization into open surgery, integrating seamlessly with existing OR platforms," Morales stated. "It enables surgeons to incorporate NIR imaging into open procedures without unnecessary complexity or workflow burden."
This sentiment highlights a critical challenge in modern medicine: "technology fatigue." As operating rooms become more crowded with disparate devices, surgeons are often burdened by complex interfaces and equipment that do not communicate with one another. By leveraging the existing IMAGE1 S infrastructure, KARL STORZ is positioning the RUBINA Lens as a "plug-and-play" solution that enhances surgical capability without disrupting the rhythm of the surgical team.
Implications for the Future of Surgery
The FDA clearance of the RUBINA Lens represents more than just a new product launch; it signals a shift in the standard of care for open surgical procedures.
Enhanced Patient Outcomes
The primary implication of this technology is the potential for improved clinical outcomes. By providing a "second set of eyes" that can see beyond the visible spectrum, surgeons can operate with greater confidence. This is particularly relevant in high-risk procedures where the margin for error is minimal. Reduced rates of postoperative complications, such as tissue ischemia or missed lymph nodes, could ultimately lead to shorter hospital stays and lower healthcare costs.
Democratization of Advanced Imaging
Historically, high-end visualization tools were reserved for robotic or specialized laparoscopic setups. The RUBINA Lens bridges the gap, ensuring that patients undergoing open surgery—often the most complex cases—benefit from the same level of diagnostic precision as those undergoing minimally invasive procedures.
The Evolution of the Operating Room
As digital surgery continues to evolve, the distinction between "open" and "closed" surgery is becoming increasingly blurred by digital overlays and augmented reality. The RUBINA Lens is a significant step toward a fully digitized operating environment. Looking ahead, it is likely that such devices will incorporate artificial intelligence (AI) to further analyze the fluorescence data, perhaps even providing automated calculations of perfusion rates or identifying anatomical structures in real-time.
Conclusion
The introduction of the KARL STORZ RUBINA Lens into the US market is a landmark event for surgical technology. By successfully translating the benefits of NIR/ICG fluorescence into the open surgical theater, KARL STORZ has provided a tool that enhances surgical precision, simplifies complex workflows, and offers a clear pathway to better patient care.
As medical centers across the United States begin to integrate this technology into their surgical suites, the industry will be watching closely to quantify the impact on patient recovery times and long-term surgical success. With its combination of 4K clarity, seamless platform integration, and clinical versatility, the RUBINA Lens is not merely a tool for today—it is a foundation for the future of precision surgery.
In a field where visibility is synonymous with safety, the RUBINA Lens ensures that the surgeon’s view is no longer limited by the constraints of the human eye.
About the Author
